Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma.

PURPOSE To compare the efficacy of stereotactic ablative radiation therapy (SABR) versus liver resection for small hepatocellular carcinoma (HCC) ≤5 cm with Child-Pugh A cirrhosis. METHODS AND MATERIALS This retrospective study included 117 patients with small HCCs with 1 or 2 nodules. Eighty-two patients received SABR (SABR group), and 35 patients underwent liver resection (resection group). Overall survival (OS) and progression-free survival (PFS) were analyzed. One-to-one matched pairs between the 2 groups were created using propensity score matching to reduce the potential confounding effect of treatment and selection bias. RESULTS There was no between-group difference in OS and PFS. Before propensity score matching, the 1-, 3-, and 5-year OS was 96.3%, 81.8%, and 70.0% in the SABR group and 93.9%, 83.1%, and 64.4% in the resection group, respectively (P=.558). The 1-, 3- and 5-year PFS was 81.4%, 50.2%, and 40.7% in the SABR group and 68.0%, 58.3%, and 40.3% in the resection group, respectively (P=.932). After propensity score matching, 33 paired patients were selected from the SABR and resection groups. The 1-, 3-, and 5-year OS was 100%, 91.8%, and 74.3% in the SABR group and 96.7%, 89.3%, and 69.2% in the resection group, respectively (P=.405). The 1-, 3-, and 5-year PFS was 84.4%, 59.2%, and 43.9% in the SABR group and 69.0%, 62.4%, and 35.9% in the resection group, respectively (P=.945). There was a similarity of hepatotoxicity between the 2 groups. The SABR group showed fewer complications, such as hepatic hemorrhage, hepatic pain, and weight loss. Acute nausea was significantly more frequent in the SABR group than in the resection group. CONCLUSION For patients with small primary HCC with 1 or 2 nodules and Child-Pugh A cirrhosis, SABR has local effects that are similar to those with liver resection. Stereotactic ablative radiation therapy has an advantage over resection in being less invasive.

[1]  Y. Matsui,et al.  Comparison of limited and anatomic hepatic resection for hepatocellular carcinoma with hepatitis C. , 2006, Surgery.

[2]  A. Alberti,et al.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications , 2004, Gut.

[3]  F. Xia,et al.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. , 2012, Journal of hepatology.

[4]  Peter Balter,et al.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2015, The Lancet. Oncology.

[5]  M. Anscher,et al.  Hepatic toxicity resulting from cancer treatment. , 1995, International journal of radiation oncology, biology, physics.

[6]  H. Bismuth,et al.  Liver Resection Versus Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients , 1993, Annals of surgery.

[7]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[8]  S. Fan,et al.  Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation , 2002, Annals of surgery.

[9]  E. Kunieda,et al.  Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients , 2014, Acta oncologica.

[10]  Manabu Watanabe,et al.  Comparison of percutaneous radiofrequency ablation and CyberKnife(®) for initial solitary hepatocellular carcinoma: A pilot study. , 2015, World journal of gastroenterology.

[11]  D. Levi,et al.  Comparison of hepatic resection and hepatic transplantation in the treatment of hepatocellular carcinoma among cirrhotic patients , 2002, Annals of Surgical Oncology.

[12]  Zahra Kassam,et al.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Lau,et al.  A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.

[14]  K. Awai,et al.  Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[15]  Jin Wook Chung,et al.  Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia , 2011, Oncology.

[16]  Mary Feng,et al.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Bruix,et al.  Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.

[18]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[19]  Jong Hoon Kim,et al.  Stereotactic Body Radiation Therapy as an Alternative Treatment for Small Hepatocellular Carcinoma , 2013, PloS one.

[20]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[21]  Yong Zeng,et al.  A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria , 2010, Annals of surgery.

[22]  T. Pawlik,et al.  Hepatobiliary cancers, version 2.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[24]  T. Su,et al.  Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients , 2016, Journal of surgical oncology.

[25]  L. Gaspar,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Pan,et al.  Subclassification of patients with solitary hepatocellular carcinoma based on post-hepatectomy survival: a large retrospective study , 2016, Tumor Biology.

[27]  W. Jang,et al.  Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis , 2016, Cancer medicine.

[28]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.